Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
- JCR’s JR-441 Primed for Japan Clinical Trial in MPS IIIA
August 30, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Padcev-Keytruda Approved in Europe for 1st Line Bladder Cancer
August 29, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Sanofi Curbs Supply of Ultra-Fast Acting Insulin Biosimilars in Japan
August 28, 2024
- PNH Drug PiaSky Approved in Europe: Roche/Chugai
August 28, 2024
- Astellas’ Hot Flash Drug Now in Global PIII for Women with Breast Cancer
August 28, 2024
- Guardant Liquid Biopsy Test Approved as CDx for Amivantamab Combo Therapy
August 28, 2024
- A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- UK OKs Eisai’s Alzheimer’s Drug, but Health Coverage Nixed
August 26, 2024
- Moderna’s JN.1-Tailored COVID Vaccine Approved in Japan
August 26, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- Xolair SC Pen Versions Go on Sale in Japan: Novartis
August 23, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…